Literature DB >> 10822307

High efficiency retroviral vectors that contain no viral coding sequences.

S S Yu1, J M Kim, S Kim.   

Abstract

Almost all currently available retroviral vectors based on murine leukemia virus (MLV) contain one or more viral coding sequences. Because these sequences are also present in the packaging genome, it has been suggested that homologous recombination may occur between the same nucleotide sequence in the packaging genome and the vector, resulting in the production of replication competent retrovirus (RCR). Up until now, it has been difficult to completely remove viral coding sequences since some were thought to be involved in the optimum function of the retroviral vector. For example, the gag coding sequence present in almost all available retroviral vectors has been believed to be necessary for efficient viral packaging, while the pol coding sequence present in the highly efficient vector MFG has been thought to be involved in achieving the high levels of gene expression. However, we have now developed a series of retroviral vectors that are absent of any retroviral coding sequences but produce even higher levels of gene expression without compromising viral titer. In these vectors, the intron and exon sequences from heterologous cellular or viral genes are present. When compared with the well-known MLV-based vectors, some of these newly developed vectors have been shown to produce significantly higher levels of gene expression for a longer period. In an experimental system that can maximize the production of RCR, our newly constructed vectors produced an absence of RCR. These vectors should prove to be safer than other currently available retroviral vectors containing one or more viral coding sequences.

Entities:  

Mesh:

Year:  2000        PMID: 10822307     DOI: 10.1038/sj.gt.3301164

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  12 in total

1.  SIN retroviral vectors expressing COL7A1 under human promoters for ex vivo gene therapy of recessive dystrophic epidermolysis bullosa.

Authors:  Matthias Titeux; Valérie Pendaries; Maria A Zanta-Boussif; Audrey Décha; Nathalie Pironon; Laure Tonasso; José E Mejia; Agnes Brice; Olivier Danos; Alain Hovnanian
Journal:  Mol Ther       Date:  2010-05-18       Impact factor: 11.454

2.  Retroviral gene therapy for X-linked chronic granulomatous disease: results from phase I/II trial.

Authors:  Hyoung Jin Kang; Cynthia C Bartholomae; Anna Paruzynski; Anne Arens; Sujeong Kim; Seung Shin Yu; Youngtae Hong; Chang-Wan Joo; Nam-Kyung Yoon; Jung-Woo Rhim; Joong Gon Kim; Christof Von Kalle; Manfred Schmidt; Sunyoung Kim; Hyo Seop Ahn
Journal:  Mol Ther       Date:  2011-08-30       Impact factor: 11.454

3.  DNA sensing-independent inhibition of herpes simplex virus 1 replication by DAI/ZBP1.

Authors:  Thanh H Pham; Ki Mun Kwon; Young-Eui Kim; Kyeong Kyu Kim; Jin-Hyun Ahn
Journal:  J Virol       Date:  2013-01-02       Impact factor: 5.103

4.  Generation of mouse and human induced pluripotent stem cells (iPSC) from primary somatic cells.

Authors:  I M Lorenzo; A Fleischer; D Bachiller
Journal:  Stem Cell Rev Rep       Date:  2013-08       Impact factor: 5.739

5.  Critical role of presenilin-dependent γ-secretase activity in DNA damage-induced promyelocytic leukemia protein expression and apoptosis.

Authors:  H Song; J Hyun Boo; K Ho Kim; C Kim; Y-E Kim; J-H Ahn; G Sun Jeon; H Ryu; D E Kang; I Mook-Jung
Journal:  Cell Death Differ       Date:  2013-01-11       Impact factor: 15.828

6.  Transmembrane Protein pUL50 of Human Cytomegalovirus Inhibits ISGylation by Downregulating UBE1L.

Authors:  Myoung Kyu Lee; Ye Ji Kim; Young-Eui Kim; Tae-Hee Han; Jens Milbradt; Manfred Marschall; Jin-Hyun Ahn
Journal:  J Virol       Date:  2018-07-17       Impact factor: 5.103

Review 7.  Current advances in retroviral gene therapy.

Authors:  Youngsuk Yi; Moon Jong Noh; Kwan Hee Lee
Journal:  Curr Gene Ther       Date:  2011-06       Impact factor: 4.391

Review 8.  Gammaretroviral vectors: biology, technology and application.

Authors:  Tobias Maetzig; Melanie Galla; Christopher Baum; Axel Schambach
Journal:  Viruses       Date:  2011-06-03       Impact factor: 5.048

9.  Positive role of promyelocytic leukemia protein in type I interferon response and its regulation by human cytomegalovirus.

Authors:  Young-Eui Kim; Jin-Hyun Ahn
Journal:  PLoS Pathog       Date:  2015-03-26       Impact factor: 6.823

10.  A Promising Vector for TCR Gene Therapy: Differential Effect of siRNA, 2A Peptide, and Disulfide Bond on the Introduced TCR Expression.

Authors:  Sachiko Okamoto; Yasunori Amaishi; Yumi Goto; Hiroaki Ikeda; Hiroshi Fujiwara; Kiyotaka Kuzushima; Masaki Yasukawa; Hiroshi Shiku; Junichi Mineno
Journal:  Mol Ther Nucleic Acids       Date:  2012-12-18       Impact factor: 10.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.